Detalhe da pesquisa
1.
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study.
Haematologica
; 109(3): 867-876, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646657
2.
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study.
Haematologica
; 109(3): 895-905, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646660
3.
Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study.
Haematologica
; 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38426292
4.
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study.
Lancet Oncol
; 24(10): 1119-1133, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37717583
5.
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis.
Ann Hematol
; 102(6): 1501-1511, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37088816
6.
Successful therapy of retroperitoneal fibrosis due to IgG4-related disease with rituximab, cyclophosphamide and glucocorticoids followed by maintenance therapy wit ritutixmab.
Vnitr Lek
; 69(E-3): 4-15, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37468330
7.
Successful treatment of SAPHO syndrome (chronic nonbacterial osteomyelitis and acne) with anakinra and denosumab. Case report and review of therapy.
Vnitr Lek
; 69(E-5): 4-14, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37827817
8.
Identification of patients at high risk of secondary extramedullary multiple myeloma development.
Br J Haematol
; 196(4): 954-962, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34726261
9.
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Lancet
; 397(10292): 2361-2371, 2021 06 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34097854
10.
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis.
Haematologica
; 107(6): 1397-1409, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34647444
11.
CAR-T cells for the treatment of relapsed/refractory multiple myeloma in 2022: efficacy and toxicity.
Neoplasma
; 69(5): 1008-1018, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35900317
12.
Proteomic analysis of the bone marrow microenvironment in extramedullary multiple myeloma patients.
Neoplasma
; 69(2): 412-424, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35037760
13.
Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data.
Neoplasma
; 69(6): 1474-1479, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36591805
14.
Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma.
Int J Mol Sci
; 23(23)2022 Nov 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36499093
15.
Langerhans cell histiocytosis (LCH). Overview of symptoms of LCH, which may lead the patients to any of these medical specialists.
Vnitr Lek
; 68(E-2): 11-21, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36208940
16.
IgG4-related disease. Clinical manifestation differential diagnosis and recent International Diagnostic Criteria for IgG4-related disease.
Vnitr Lek
; 68(E-5): 4-19, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36283812
17.
Multicentric Castlemans disease. Symptoms, diagnostics and therapy.
Vnitr Lek
; 68(1): 41-53, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35459346
18.
Therapy of immunoglonuline IgG4 related disease (IgG4-RD).
Vnitr Lek
; 68(E-6): 15-22, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36316207
19.
Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia.
Br J Haematol
; 195(1): 95-107, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34500493
20.
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
Br J Haematol
; 192(5): 869-878, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33216361